1.Anaplastic Thyroid Cancer: Experience of the Philippine General Hospital.
Tom Edward LO ; Cecilia Alegado JIMENO ; Elizabeth PAZ-PACHECO
Endocrinology and Metabolism 2015;30(2):195-200
BACKGROUND: Anaplastic thyroid cancer (ATC) is a rare type of thyroid malignancy and one of the most aggressive solid tumors, responsible for between 14% and 50% of the total annual mortality associated with thyroid cancer. METHODS: A retrospective study was made of all ATC cases diagnosed by biopsy in the Philippine General Hospital between 2008 and 2013. RESULTS: A total of 15 patients were identified, with a median age at diagnosis of 63 years. All tumors were at least 6 cm in size upon diagnosis. All patients had a previous history of thyroid pathology, presenting with an average duration of 11 years. Eleven patients presented with cervical lymphadenopathies, whereas seven exhibited signs of distant metastases, for which the lungs appeared to be the most common site. More than 70% of the patients presented with a rapidly growing neck mass, leading to airway obstruction. Only three patients were treated using curative surgery; the majority received palliative and supportive forms of treatment. In addition, only three patients were offered radiotherapy. Chemotherapy was not offered to any patient. Only two patients were confirmed to still be alive during the study period. The median survival time for the other patients was 3 months; in the majority of cases the patient died within the first year following diagnosis. CONCLUSION: Our experience with ATC demonstrated concordance with other institutions with respect to current clinical profile, presentation, and prognosis. An absence of distant metastases and lymph node involvement was associated with improved survival outcomes, whereas age at diagnosis and tumor size did not affect survival. Curative surgery offers the most effective means of prolonging survival. Radiotherapy and chemotherapy in combination with surgery represents a promising treatment strategy.
Airway Obstruction
;
Biopsy
;
Diagnosis
;
Drug Therapy
;
Hospitals, General*
;
Humans
;
Lung
;
Lymph Nodes
;
Mortality
;
Neck
;
Neoplasm Metastasis
;
Pathology
;
Philippines
;
Prognosis
;
Radiotherapy
;
Retrospective Studies
;
Thyroid Gland
;
Thyroid Neoplasms*
2.Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience.
Sun Min LIM ; Sang Joon SHIN ; Woong Youn CHUNG ; Cheong Soo PARK ; Kee Hyun NAM ; Sang Wook KANG ; Ki Chang KEUM ; Joo Hang KIM ; Jae Yong CHO ; Yun Kyoung HONG ; Byoung Chul CHO
Yonsei Medical Journal 2012;53(2):352-357
PURPOSE: Anaplastic thyroid cancer is known to have a poor prognosis due to its aggressive and rapid metastasis with median survival of less than 6 months. Multimodal treatment involving surgery and chemoradiotherapy has been used to improve the survival of patients. Here, we retrospectively review of treatment outcome of 13 consecutive patients who were treated at a single center. MATERIALS AND METHODS: We retrospectively reviewed medical records of 13 anaplastic thyroid cancer patients who received multidisciplinary treatment between 2006 and 2010. Kaplan-Meier survival curve was used to analyze progression-free survival and overall survival of patients. RESULTS: The median patient age at diagnosis was 69 years, and six patients had stage IVc diseases. Eight patients received primary surgery followed by radiotherapy or concurrent chemoradiotherapy (CCRT). Five patients received weekly doxorubicin-based definitive CCRT, but only one patient's condition remained stable, while the rest experienced rapid disease progression. The median progression-free survival was 2.8 months (95% CI, 1.2-4.4 months), and the median overall survival was 3.8 months (95% CI, 3.0-4.6 months). CONCLUSION: Patients with anaplastic thyroid cancer showed poor prognosis despite multimodality treatment. Therefore, identification of novel therapeutic targets is warranted to take an effective mode of treatment.
Aged
;
Aged, 80 and over
;
Antineoplastic Agents/therapeutic use
;
Combined Modality Therapy
;
Disease-Free Survival
;
Doxorubicin/therapeutic use
;
Female
;
Humans
;
Male
;
Middle Aged
;
Retrospective Studies
;
Thyroid Neoplasms/*drug therapy/mortality
;
Treatment Outcome
3.Thyroid Cancer in Pediatric Age: A Single Institution Experience.
Hyo Jun KIM ; Ji Won HAN ; Joong Kee YOUN ; Hee Beom YANG ; Chaeyoun OH ; Hyun Young KIM ; Sung Eun JUNG ; Kwi Won PARK
Journal of the Korean Association of Pediatric Surgeons 2017;23(2):42-47
PURPOSE: Thyroid cancer is a rare disease in pediatric population, but its incidence rate is increasing. The aim of this report is to present a single institution experience of pediatric thyroid cancer and to identify clinical features, predisposing factors, and postoperative course of pediatric thyroid cancer. METHODS: We retrospectively reviewed 35 pediatric patients who underwent operation due to thyroid cancer at Seoul National University Children's Hospital between May 1997 and January 2017. The median follow-up period was 70 months (range, 5–238 months). RESULTS: The mean age at operation was 12.0±5.91 years and 27 patients were female. The underlying conditions in patients included history of chemoradiotherapy for previous other malignancies (n=4), hypothyroidism (n=3), history of chemotherapy (n=2), family history of thyroid cancer (n=1) and history of radiation therapy (n=1). The initial symptoms were palpable neck mass (n=21) and incidental findings (n=11). Total thyroidectomy (n=30) or unilateral lobectomy (n=5) were performed. There were 15 postoperative complications including transient hypocalcemia in 14 patients and Horner's syndrome in 1 patient. The most common pathologic cell type was papillary thyroid cancer (n=29). Extrathyroid extension and lymph node invasion were found in 25 patients and 27 patients, respectively. Thirteen patients showed multifocality. During follow-up period, 5 patients underwent additional operation because of tumor recurrence in lymph nodes. Lung metastasis was detected in 3 patients at the time of diagnosis and in 3 patients during follow-up period. The mortality rate was zero and mean disease-free survival was 83.7±47.9 months. CONCLUSION: Pediatric thyroid cancer has lower mortality rate and recurrence rate as seen in this study despite the advanced stage at diagnosis. A thorough follow-up of patients with an underlying condition such as history of chemoradiotherapy and understanding new pediatric guideline can be helpful to maximize patients' survival and prognosis.
Causality
;
Chemoradiotherapy
;
Diagnosis
;
Disease-Free Survival
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Horner Syndrome
;
Humans
;
Hypocalcemia
;
Hypothyroidism
;
Incidence
;
Incidental Findings
;
Lung
;
Lymph Nodes
;
Mortality
;
Neck
;
Neoplasm Metastasis
;
Pediatrics
;
Postoperative Complications
;
Prognosis
;
Rare Diseases
;
Recurrence
;
Retrospective Studies
;
Seoul
;
Thyroid Gland*
;
Thyroid Neoplasms*
;
Thyroidectomy